baber/WOPTO huggingface dataset:
Patent CA-2389635-A1 (CA)
Inventor: NEUDORF DAVID A
IPC: C22B/
Filed: 2000-10-25
Abstract: A process is provided for leaching nickeliferous laterite ores by hydrometallurgical methods at temperatures below the boiling point of the pu lp and at atmospheric pressure from which high overall nickel and cobalt extractions are obtained. The high iron fraction of the laterite, referred t o as limonite, is first contacted with a concentrated mineral acid to partiall y or completely dissolve the iron and nickel in solution. During this process,  a reducing agent is used to keep the redox potential in solution below 1000 mV  to enhance cobalt dissolution and more advantageously between 1000 and 900 m V to avoid reduction of ferric iron. Further mixing of the leach slurry in the  presence of sodium, potassium, or ammonium will allow the formation of iron jarosite at ambient pressure. The resulting acid from iron hydrolysis is neutralized with the low iron fraction of the laterite ore (saprolite) dissolving nickel into solution. The resulting slurry can then be treated wi th conventional methods to recover nickel and cobalt from solution.
Patent CA-2389681-A1 (CA)
Inventor: KAWANISHI YASUYUKI
IPC: A61K31/341
Filed: 2000-11-21
Abstract: NPYY5 receptor antagonists which contain compounds represented by general formula (I), prodrugs thereof, pharmaceutically acceptable salts thereof or solvates of the same wherein R1 represents lower alkyl, cycloalkyl, etc.;  R2 represents hydrogen, lower alkyl, etc.; n is 1 or 2; X represents lower alkylene, lower alkenylene, arylene, cycloalkylene, etc.; Y represents CONR7, CSNR7, NR7CO, NR7CS, etc.  (wherein R7 represents hydrogen or lower alkyl);  and Z represents lower alkyl, an optionally substituted hydrocarbon cycle, an optionally substituted heterocycle, etc.
Patent CA-2390295-A1 (CA)
Inventor: STEINER MITCHELL S
IPC: A61K9/10
Filed: 2000-11-08
Abstract: This invention relates to the chemoprevention of prostate cancer and, more particularly, to a method of suppressing or inhibiting latent prostate cancer comprising administering to a mammalian subject a chemopreventive agent and analogs and metabolites thereof. The chemopreventive agent prevents, prevents recurrence of, suppresses or inhibits prostate carcinogenesis; and treats prostate cancer.
Patent CA-2391382-A1 (CA)
Inventor: NARLA RAMA K
IPC: A61P35/02
Filed: 2000-11-15
Abstract: Synthetic Phorboxazole A and derivatives thereof for the treatment of cancer, including inhibition of cancer cell growth, induction of apoptosis, and inhibition of metastises.
Patent CA-2393832-A1 (CA)
Inventor: SILVER BRIAN H
IPC: A61M1/06
Filed: 2000-12-07
Abstract: A breastpump (fig. 1) which can be programmed to generate, among other things, a plural-ity of differing milk expression (extraction) sequence, or curves is disclosed. In one embodiment of the inven-tion, a motorized pump (e.g., compressed air, battery and/or house current) (fig. 17) is provided with a micro-processor-based controller (60). Cards (figs. 11-14), with microprocessor "chip" (61), containing different suction curves adapted for varying condition and ob-jectives are included for programming the controller in this embodiment.
Patent CA-2394336-A1 (CA)
Inventor: MORRIS DONALD P
IPC: B23C5/08
Filed: 2000-11-06
Abstract: A slotting cutter (10) including a support disc (12) rotatable in a predetermined direction on a central axis. The support disc (12) is of a generally cylindrical shape having a first side (50) and a second side (46), and an outer periphery (14). A plurality of pockets (22) including a cartridge assembly (54) are staggered about the outer periphery (14) of the support disc (12) and include a cutting insert (24) secured to each cartridge assembly.
Patent CA-2395496-A1 (CA)
Title: Solid or hollow plastics profiles, particularly for use in composite profiles
Inventor: ENSINGER WILFRIED
IPC: E06B3/263
Filed: 2000-08-11
Abstract: In order to develop known solid or hollow plastics profiles, particularly those as used to absorb tensile, bending, and/or pressure loads, such as are primarily used as insulating segments in composite profiles containing metallic profiled elements, such that the problems normally encountered with the use of higher filler contents of the plastics material used, intended to favorably influence the expansion characteristics, are ressolved, the invention proposes that said profiles contain a surface layer of a solid, non-porous first plastics material and, in the core region, a fine-pored cellular structure of a second plastics material.
Patent CA-2397139-A1 (CA)
Inventor: LAGUETTE STEPHEN W
IPC: A61F2/16
Filed: 2001-01-10
Abstract: Iris fixated intraocular lenses include an optic and at least one fixation member or haptic. The fixation member is joined to the optic and has a distal segment including a through-iris portion adapted to extend through an iris hole, and an anchor portion. The anchor portion has or is adapted to have an anchor structure positioned to be disposed proximate to a side of the iris so as to be effective in fixating the intraocular lens to the iris. The anchor structure may be formed prior to inserting the intraocular lens in the eye or may be formed after the intraocular lens is inserted in the eye. Methods for inserting such intraocular lenses in the eye are also provided.
Patent CA-2398927-A1 (CA)
Inventor: TANG WANCHUN
IPC: A61K31/00
Filed: 2000-11-30
Abstract: L'invention concerne des procédés, des formulations, et des ensembles destinés à réanimer un patient victime d'un arrêt cardiaque, à améliorer l'efficacité de la réanimation cardio-pulmonaire, à traiter l'hypotension post-réanimatoire, et à réduire les risques d'arythmies ventriculaires et de dysfonctionnement myocardiaque après réanimation cardio-pulmonaire. Les procédés et agents antérieurs causent souvent des effets inotropiques ou chronotropiques pouvant entraîner des dysfonctionnements myocardiaques post-réanimatoires gênants. Le procédé selon l'invention consiste à administrer une quantité thérapeutique efficace d'un agoniste de .alpha.¿2?-récepteur ne passant pas la barrière hémato-encéphalique, tel que la .alpha.-méthylnorépinéphrine, afin d'améliorer la réanimation cardio-pulmonaire.
Patent CA-2399315-A1 (CA)
Title: Short motion swim fin
Inventor: MASSE ROGER E
IPC: A63B21/008
Filed: 2002-08-21
Abstract: A short tapered fin, that when worn on the forward portion of the foot, acts as a lever to the foot with the fulcrum of that lever being on the underside of the foot. The effect of this lever action stretches the arch of the foot on every downward kick. The rigidity of the fin is also adjustable to the particular swimmer by varying the taper of the fin. The short tapered swim fin functions as a stretching device to stretch and increase the arch of the foot, and as a training device to strengthen the leg muscles that are used with the motions of flutter kick.      This invention is a training swim fin that when used over time will improve a swimmer's performance for competitive swimming without fins.
Patent CA-2402519-A1 (CA)
Title: Process for manufacturing paclitaxel and 13-acetyl-9-dihydrobaccatin iii
Inventor: LIU JIAN
IPC: C07D305/14
Filed: 2001-03-09
Abstract: A process for obtaining paclitaxel and other taxanes from a source containing taxanes. The process involves extract-ing taxane compounds from the source into an organic solvent and passing this composition through a distribution chromatography column and eluting taxane compounds with the dry distribution column. The eluted taxane compounds are isolated by further processing techniques.
Patent CA-2403689-A1 (CA)
Title: Waveguide optical phase shifter
Inventor: AL-HEMYARI KADHAIR
IPC: G02B6/26
Filed: 2000-11-22
Abstract: An optical phase shifter including a constant phase shift element or a variable phase shift element, each introducing a desired and predetermined phase shift into an optical signal passing through the phase shifter. The phase shifter has coaxial first and second waveguides each with a core defining an optical path, through the first waveguide and having an output facet, and which waveguides are separated from each other by a predetermined distance. The phase shift element is disposed between the waveguides and an actuator is coupled to the phase shift element for causing selective movement of the phase shift element.
Patent CA-2406967-A1 (CA)
Inventor: SUENOBU HIROYUKI
IPC: C04B38/06
Filed: 2002-02-22
Abstract: A method for producing a ceramic structure, which comprises mixing a raw material for a ceramic, a foamed resin and optionally, a forming aid, formin g the resultant mixture, and then firing the formed article, to thereby provid e a porous ceramic structure. The method allows the production of a ceramic structure having a high porosity with the use of a reduced amount of a combustible powder.
Patent CA-2408688-A1 (CA)
Inventor: SEHRA SARITA
IPC: C07K16/44
Filed: 2001-06-06
Abstract: The present invention relates to a method to induce the CD4+ Th1 immune response, eventually combined with a repression of the Th2 mediated activities, comprising the administration of an IgG isotype antibody which is not an IgG1 isotype antibody. Preferentially said antibody is an IgG2a and/or IgG2b isotype anti-allergen antibody. The shift from a Th2 response towards a mixed Th1/Th2 response is particularly useful in the treatment of diseases such as asthma.Because the method described corrects the immuno-pathological cause of the disease, this is the polarised Th2 response against allergen, rather than its consequences, a sustained cure from asthma can be achieved instead of a transient reduction of symptoms.
Patent CA-2410070-A1 (CA)
Title: Steering device for personal watercraft
Inventor: NAKAJIMA JUN
IPC: B63H25/02
Filed: 2002-10-29
Abstract: In a steering device for a personal watercraft including a handle holder 42 fitted to a watercraft body 11, a steering shaft 41 passing through the handle holder 42, and a handle 43 fitted to the upper end of the steering shaft 41, the steering shaft 41 is provided with a groove 54, and a holding member 48 provided in the handle holder 42 is fitted into the groove 54, whereby movement of the steering shaft 41 in the axial direction is restricted. A flange or the groove has such a shape that its width can be reduced, and when the holding member is fitted by setting the width to be small and taking dimensional dispersions into account, the chattering between the flange or the groove and the holding member can be reduced. In view of this, the steering shaft is provided with the flange or the groove, and the holding member provided in the handle holder is fitted to the flange or the groove, so that movement of the steering shaft in the axial direction can be restrained. As a result, a steering device enhanced in operation feeling can be realized.
Patent CA-2410298-A1 (CA)
Title: Book security device
Inventor: SHESLOW RICHARD MYRON
IPC: B42D3/10
Filed: 2001-05-22
Abstract: A security device (10) for books comprising a receptor (20) adapted to fit behind the spine of a book, a connector flap (30) adapted to be secured to the receptor and to locate between and parallel with the pages of the book, and means (50) to lock the connector flap (30) to the receptor (20) to entrap the book.
Patent CA-2412350-A1 (CA)
Inventor: CHENG HOWARD
IPC: A44C25/00
Filed: 2001-06-07
Abstract: An invisible connector assembly for a beaded strand of jewelry includes solid connector posts (17, 21) mounted in through-bores (16, 20) in the end beads of the strand. One post (17) is provided with a threaded stud (18) extending axially from the bead, and the other post (21) is tapped within the bore of the bead (22) to receive the threaded stud. The opposite end of each connection post (17, 21) is provided with a swiveling eye (23) for connection to one end of the string mounting the remaining beads of the strand.
Patent CA-2414637-A1 (CA)
Inventor: STRENGELL REETTA
IPC: D21H27/10
Filed: 2002-12-18
Abstract: The invention relates to a process for manufacturing liquid packaging board, in which process a board pulp is treated with a percarboxylic acid by adding to the pulp percarboxylic acid in an amount of 0.5 - 5 kg/ton of dry pulp, indicated as a 100 per cent percarboxylic acid, whereafter, or simultaneously with the percarboxylic acid treatment, sizing is carried out with a combination of a resin size and a neutral size, which is followed by board forming. The manufactured board has good resistance to liquid penetration.
Patent CA-2415670-A1 (CA)
Inventor: SORENSEN PER
IPC: F25D21/14
Filed: 2001-07-13
Abstract: La présente invention concerne un dispositif de réfrigération de produits (12) contenus dans un système de transport. Il comporte au moins un conduit descendant définissant une partie supérieure et une partie inférieure. La partie supérieure est agencée de façon à être alimentée en produits provenant d'un dispositif d'alimentation (21). La partie inférieure comporte un orifice de sortie (33) des produits. Le dispositif est caractérisé en ce que l'un au moins des conduits descendants (31) et raccordé, au niveau de sa partie supérieure ou au voisinage de celle-ci, à un canal d'alimentation (41) en air provenant d'un dispositif de réfrigération d'air extérieur (61). Ce conduit descendant (31) se termine de préférence en sa partie inférieure par une pièce de terminaison (34) comportant au moins un orifice de décharge, raccordé à un conduit de ventilation (35). Ce conduit de ventilation (35) est de préférence raccordé directement ou indirectement à la prise d'air (62) destinée au dispositif de réfrigération (61). L'invention concerne également un procédé de réfrigération de produits contenus dans un système de transport.
Patent CA-2418215-A1 (CA)
Title: Novel fibroblast growth factor (fgf23) and methods for use
Inventor: STROM TIM MATTHIAS
IPC: C12Q1/68
Filed: 2001-07-10
Abstract: The invention relates to novel nucleic acids encoding a fibroblast growth factor-23 (FGF23) and proteins encoded thereby, mutations in which are associated with autosomal dominant rickets (ADHR). The invention further relates to methods of diagnosing and treating hypophosphatemic and hyperphosphatemic disorders comprising inhibiting or stimulating, respectively, the biological activity of FGF23 in a patient. The invention also relates to methods of treating osteoporosis, dermatomyositis, and coronary artery disease comprising stimulating the biological activity of FGF23 in a patient.
Patent CA-2418349-A1 (CA)
Inventor: HIKICHI NAOKO
IPC: C03C21/00
Filed: 2003-02-04
Abstract: As a feature of a glass substrate having at least one fine hole according to the invention, a side wall surface of the fine hole is connected to each surface of the glass substrate by a curved surface as a boundary portion between the two. As another feature of the glass substrate, a layer denatured by machining is removed from the inner wall surface of the fine hole and the boundary portion between the wall surface and each surface of the glass substrate. The fine hole is produced by: forming a fine hole in a glass substrate by machining or laser machining; and then applying liquid-phase chemical etching to surfaces of the glass substrate and the fine hole. On this occasion, it is desirable that the etching liquid used for the liquid-phase chemical etching is either of an aqueous solution of hydrofluoric acid and an aqueous mixture solution of hydrofluoric acid and ammonium fluoride.
Patent CA-2420490-A1 (CA)
Inventor: BEASLEY ELLEN M
IPC: C12N9/64
Filed: 2001-08-23
Abstract: La présente invention concerne des séquences d'acides aminés de peptides codés par des gènes appartenant au génome humain: les peptides protéasiques. Plus particulièrement, l'invention se rapporte à des molécules peptidiques et à des molécules d'acides nucléiques isolées, à des méthodes d'identification d'orthologues et de paralogues de ces peptides protéasiques, ainsi qu'à des méthodes d'identification de modulateurs desdits peptides protéasiques.
Patent CA-2420690-A1 (CA)
Inventor: PRITCHARD ANDREW H
IPC: G06F/
Filed: 2001-08-10
Abstract: Financial management systems (100) and methods for development and administration of investment trusts which may be traded as a securities are provided. These trusts may be based on underlying investment instruments optimally selected to provide dividends and equity, and the trusts' value may reflect accrued investment income and maintenance expenses. The financial management systems (100) may periodically evaluate and report the performance of the investment trust (112), and may also permit investors in the trusts to redeem their ownership in the trust for cash or investment of the trust.
Patent CA-2421043-A1 (CA)
Title: Method for analysis of oligonucleotide analogs
Inventor: WELLER DWIGHT D
IPC: C12Q1/6816
Filed: 2001-08-30
Abstract: Disclosed are methods for separating, detecting, quantitating and/or isolating predominantly uncharged oligonucleotide analogs, by resolving duplexes of such molecules with complementary or near-complementary DNA or charged DNA analogs.  The DNA or charged analog may be labeled for detection purposes.
Patent CA-2424865-A1 (CA)
Title: Method of absorption-desorption of hydrogen storage alloy and hydrogen storage alloy and fuel cell using said method
Inventor: YAMASHITA SHINICHI
IPC: H01M8/06
Filed: 2000-10-03
Abstract: A method of absorption-desorption of a hydrogen storage alloy, characterized in that the temperature (T2) of a hydrogen storage alloy in the last stage of a hydrogen desorbing step is a temperature higher than the temperature (T1) of the alloy in the initial stage of the hydrogen desorbing step (that is, T2 >  T1), and said temperature (T2) in the last stage is a temperature such that the hydrogen pressure on the demarcation point of the plateau region of a PCT  curve and the slope region adjacent to it is 0.08 MPa or higher at the temperature. REFERENCE:
Patent CA-2426151-A1 (CA)
Inventor: MORRIS MARY M
IPC: A61N1/05
Filed: 2001-10-04
Abstract: L'invention concerne une électrode de défibrillation cardiaque transveineuse constitué d'un conducteur bobiné continu placé dans une couche d'isolation. Une partie du conducteur bobiné est exposée en tant qu'électrode de défibrillation. Afin d'améliorer la visualisation fluoroscopique de l'électrode exposée durant l'implantation, l'extrémité de celle-ci est marquée au moyen d'un élément radio-opaque. Cet élément peut être un adhésif rempli de matière radio-opaque qui est utilisée pour venir combler le dessous de la couche d'isolation. Dans un autre mode de réalisation, un tube fabriqué à partir de matière radio-opaque peut être placé entre la couche d'isolation et le conducteur bobiné.
Patent CA-2432591-A1 (CA)
Inventor: RAMANATHAN CHANDRA
IPC: C12N15/12
Filed: 2001-12-20
Abstract: L'invention concerne de nouveaux polynucl~otides codant pour des polypeptides de HLRRBM1 et des fragments et des homologues de ces derniers. L'invention concerne ~galement des vecteurs, des cellules hÙtes, des anticorps, et des proc~d~s de recombinaison et synth~tiques destin~s ~ produire ces polypeptides. L'invention concerne en outre des m~thodes diagnostiques et th~rapeutiques destin~es ~ appliquer ces nouveaux polypeptides HLRRBM1 au diagnostic, au traitement et/ou ~ la pr~vention de diverses maladies et/ou de divers troubles li~s ~ ces polypeptides, notamment des maladies/troubles immunitaires. L'invention concerne enfin des proc~d~s de criblage destin~s ~ identifier des agonistes et des antagonistes des polynucl~otides et des polypeptides de la pr~sente invention.
Patent CA-2435121-A1 (CA)
Inventor: O'REILLY MARK ANTHONY
IPC: A61P11/06
Filed: 2002-01-10
Abstract: Published without an
Patent CA-2440018-A1 (CA)
Inventor: WOOLSTON ROBERT
IPC: A61M5/20
Filed: 2002-03-26
Abstract: Injection devices are known for the self administration of medicament by patients in which the medicaments is typically contained within a cartridge located within the injection device. It is a problem that injection devices should be small enough to fit into a jacket pocket or a hand bag without difficulty. Also, the injection device must be of a size that enables a piston or similar used to drive a cartridge bung within the cartridge to be moved both to a maximum dispense position within the cartridge and to be fully withdrawn from the cartridge to allow for replacement of the cartridge. A  drive mechanism for an injection device is disclosed in which a piston (48) is successively moved along the first axis to drive a bung (20) into a medicament cartridge (18), a displacement mechanism comprising a dose setting spindle (30) is disposed along a second axis, the second axis being parallel to the first axis, transmission means connected between the dose setting spindle (30) and the piston (20), and displacement means to displace the dose setting spindle (30) with respect to the medicament cartridge (18), a movement of the displacement means in a first direction causing movement of the dose setting spindle (30) and the piston (20) in the first direction.
Patent CA-2441833-A1 (CA)
Inventor: SKINNER ROBIN G
IPC: F16B5/00
Filed: 2003-09-19
Abstract: A mounting bracket for a compressor. The mounting bracket includes a mounting member and an elongate bracing member. The mounting member is secured to the housing of the compressor has a central support section in substantial registry with the housing. The mounting member includes two legs which extend from opposite ends of the central support section. The first and second legs respectively include first and second distal portions. The bracing member may be secured to the mounting member with two swaged connections. The swaged connections each define an aperture through the bracing member and the mounting member. A method of mounting a compressor is also provided. The method utilizes a mounting bracket having a bracing member which is secured to a mounting member by deforming at least one of the bracing member and the mounting member into engagement with the other of the bracing member and the mounting member.
Patent CA-2442010-A1 (CA)
Inventor: QI BAOXIU
IPC: C12P7/64
Filed: 2002-03-26
Abstract: The invention relates to a new elongase gene having the sequence SEQ ID NO: 1 or its derivatives, to a gene construct comprising this sequence or its derivatives and to its use. The inventive nucleic acid sequence encodes a polypeptide which elongates .alpha.-linolenic acid (C18:3 d9, 12, 15) by at least two carbon atoms whereas .gamma.-linolenic acid (C 18:3 d6, 9, 12) is not elongated. The invention additionally relates to vectors or organisms comprising an elongase gene having the sequence SEQ ID NO: 1 or its derivatives. The invention further relates to a process for the production of polyunsaturated fatty acids (=PUFAs) with an organism which comprises the elongase gene and which organism produces high amounts of oils and especially oils with a high content of unsaturated fatty acids. Additionally the invention relates to an oil and/or fatty acid composition with a higher content of polyunsaturated C20 or C22 fatty acids with at least two double bonds and/or to a triacylglycerol composition with a higher content of said polyunsaturated fatty acids.
Patent CA-2443997-A1 (CA)
Title: Method of wcdma coverage based handover triggering
Inventor: SCHWARZ UWE
IPC: H04J13/00
Filed: 2002-05-15
Abstract: A method of triggering IF or IS handover between two WCDMA carriers or a WCDMA  carrier and a GSM carrier. Six triggering conditions are used to initiate the search for an alternative network connection by starting the handover measurements. They are: a) mobile unit (15, figure 9) power above a threshold for longer than a specified time; b) connection base (70) power downlink power above a threshold longer than a specified time; c) mobile unit (15) power has reached a max value a specified number of times; d) SIR at the base (70) has exceeded a threshold value for a period of time; e) mobile terminal (15) power has exceeded a threshold and the gradient of the power control signature indicates sudden rise to maximum power; and f) pilot power measured at the mobile (15) has fallen below a threshold for longer than a specified time.